Fig. 1 · Structure

Documents & Downloads

Rasagiline

Cat. No. A11111 CAS 136236-51-6

MAO B inhibitor

Rasagiline is a selective irreversible inhibitor of MAO-B (monoamine oxidase-B).

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
rMAO-B IC50 4.43 nM
rMAO-A IC50 412 nM

Cellular Effect

Cell Line Activity Value Description Reference
BTI-TN-5B1-4 IC50 0.069 μM Inhibition of human recombinant microsomal MAO-B expressed in baculovirus infected BTI-TN-5B1-4 cells using p-tyramine as substrate assessed as production of H2O2 incubated for 15 mins followed by substrate addition measured over 15 mins by fluorimetric a [PMID: 23474901]
BTI-TN-5B1-4 IC50 13 nM Inhibition of human recombinant MAO-B expressed in baculovirus infected BTI-TN-5B1-4 insect cells assessed as decrease in H2O2 production using p-tyramine as substrate incubated for 20 mins by horse-radish peroxidase/amplex red-based fluorescence method [PMID: 31265934]
BTI-TN-5B1-4 IC50 13 nM Inhibition of human recombinant MAO-B expressed in baculovirus infected BTI-TN-5B1-4 insect cells using p-tyramine as substrate preincubated for 15 mins and measured after 45 mins by resorufin-based fluorescence assay [PMID: 30522087]
BTI-TN-5B1-4 IC50 147.3 μM Inhibition of human microsomal MAO-B expressed in baculovirus infected BTI-TN-5B1-4 cells assessed as reduction in 4-hydroxyquinoline formation using kynuramine as substrate preincubated with substrate for 10 mins followed by enzyme addition by spectropho [PMID: 31711793]
BTI-TN-5B1-4 IC50 16.44 μM Inhibition of human recombinant microsomal MAO-A expressed in baculovirus infected BTI-TN-5B1-4 cells using p-tyramine as substrate assessed as production of H2O2 incubated for 15 mins followed by substrate addition measured over 15 mins by fluorimetric a [PMID: 23474901]
BTI-TN-5B1-4 IC50 3.65 μM Inhibition of human microsomal MAO-A expressed in baculovirus infected BTI-TN-5B1-4 cells assessed as reduction in 4-hydroxyquinoline formation using kynuramine as substrate preincubated with substrate for 10 mins followed by enzyme addition by spectropho [PMID: 31711793]
BTI-TN-5B1-4 IC50 49.66 nM Inhibition of human microsomal MAO-B expressed in recombinant baculovirus infected insect BTI-TN-5B1-4 cells assessed as reduction in H2O2 production using p-tyramine as substrate after 15 mins by fluorescence assay [PMID: 27244485]
BTI-TN-5B1-4 IC50 52974 nM Inhibition of human microsomal MAO-A expressed in recombinant baculovirus infected insect BTI-TN-5B1-4 cells assessed as reduction in H2O2 production using p-tyramine as substrate after 15 mins by fluorescence assay [PMID: 27244485]
BTI-TN-5B1-4 IC50 680 nM Inhibition of human recombinant MAO-A expressed in baculovirus infected BTI-TN-5B1-4 insect cells assessed as decrease in H2O2 production using p-tyramine as substrate incubated for 20 mins by horse-radish peroxidase/amplex red-based fluorescence method [PMID: 31265934]
BTI-TN-5B1-4 IC50 680 nM Inhibition of human recombinant MAO-A expressed in baculovirus infected BTI-TN-5B1-4 insect cells using p-tyramine as substrate preincubated for 15 mins and measured after 45 mins by resorufin-based fluorescence assay [PMID: 30522087]
SH-SY5Y IC50 2700 μM Cytotoxicity against human SH-SY5Y cells measured after 24 hrs by MTT assay [PMID: 33360800]
SIM-A9 IC50 2900 μM Cytotoxicity against mouse SIM-A9 cells measured after 24 hrs by MTT assay [PMID: 33360800]

12 records · Scroll to view more

Rasagiline Research Summary

This section summarizes 1 in vitro study and 3 in vivo studies of Rasagiline from 3 published references. In vivo models include male Sprague-Dawley rats; CD157 KO mice.

Rasagiline In Vitro Studies

Rasagiline was added to the perfusion fluid of rat striatal slices from male Wistar rats following rotenone preincubation and preperfusion. It did not decrease oxidative stress-induced pathological tritium release compared with H2O2-treated slices. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Rasagiline and oxidative stress-induced tritium release in striatal slices

Cell-based study · male Wistar rats; rat striatal slices [1]

Rat striatal slices from male Wistar rats received Rasagiline in the perfusion fluid following rotenone preincubation and preperfusion. Rasagiline did not decrease oxidative stress-induced pathological tritium release compared with H2O2-treated slices.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
net release evoked by H2O2 calculated by the area-under-the-curve methodReported result After rotenone preincubation (10 μM, 60 min) and 60 min preperfusion: rasagiline (10 nM), did not decrease oxidative stress-induced pathological tritium release.[1]

Literature-Reported Treatment Conditions

Treatment concentration
10 nM
Exposure duration
18 min before the perfusion with H2O2 and onwards
Method
added to the perfusion fluid
Co-treatment
Other interventions in this design: rotenone 10 μM; H2O2 250 μM. Compound effect isolated by the comparison: H2O2 treated slices.
Reported limits
Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Rasagiline

Evidence for Rasagiline as the mesylate form reported in the paper, not the free base/neutral form supplied as A11111; no salt equivalence, dose conversion or lot validation.

Results > Effect of the compounds on oxidative stress-induced pathological [3H]dopamine release in the rotenone pretreated rat striatum (S2, S4); Methods > [3H]dopamine release experiments in rat striatal slices (S86, S88, S90, S91); Methods > Tyrosine hydroxylase (TH) immunohistochemistry following in vitro incubation (S120, S123); Fig. 1 legend (S234, S237, S240, S242); Fig. 2 legend (S246)

net release evoked by H2O2 calculated by the area-under-the-curve method: net release evoked by H2O2 calculated by the area-under-the-curve method; comparator: H2O2 treated slices — Results > Effect of the compounds on oxidative stress-induced pathological [3H]dopamine release in the rotenone pretreated rat striatum (S2, S4); Fig. 1 legend (S240)

Rasagiline In Vivo Studies

In male Sprague-Dawley rats, Rasagiline administered by gavage before and during rotenone treatment ameliorated cataleptic behavior compared with the rotenone-only model group. In CD157 KO mice, a single subcutaneous administration of Rasagiline reduced FST immobility time compared with saline-treated mice. In male C57/Bl6 mice, intraperitoneal Rasagiline pretreatment did not restore dopamine metabolite levels in the presence of MPTP and further decreased DOPAC and HVA levels. [2,3,1]

Rasagiline and rotenone-induced cataleptic behavior in rats

Animal study · Male Sprague-Dawley rats [2]

Male Sprague-Dawley rats received Rasagiline by gavage before co-treatment with rotenone. Rasagiline ameliorated rotenone-induced cataleptic behavior compared with the rotenone-only model group.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
descent latency in the bar (Fig. 2A) and grid test (Fig. 2B)Reported result 0.3 mg/kg rasagiline: ameliorated the cataleptic behavior induced by rotenone.[2]

Conditions shared by the study groups

Route
gavage
Treatment course
Rats in group 7 received rasagiline for 10 days and were then co-treated with rotenone for 4 weeks. During a 4-week co-treatment period in groups 1 and 4-7, saline, different doses of fucoidan and rasagiline were administrated once a day, while rotenone and DMSO + sunflower oil were given 5 times a week.
Vehicle
0.5% hydroxypropyl methyl cellulose
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Rasagiline 0.3 mg/kgmodel group (rotenone only)0.3 mg/kg rasagiline: ameliorated the cataleptic behavior induced by rotenone.[2]
Rasagiline 0.3 mg/kg
Model: Male Sprague-Dawley rats
Methods and source locations

Compound reported in the paper: Rasagiline

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

MATERIALS AND METHODS > Animals (S7); MATERIALS AND METHODS > Experimental design (S14, S16, S17, S18, S20); MATERIALS AND METHODS > In situ studies of mitochondrial respiratory function (S87, S88); RESULTS > Effects of fucoidan on catalepsy in PD rats (S115, S119)

descent latency in the bar (Fig. 2A) and grid test (Fig. 2B): descent latency in the bar (Fig. 2A) and grid test (Fig. 2B); comparator: model group (rotenone only) — MATERIALS AND METHODS > In situ studies of mitochondrial respiratory function (S87); RESULTS > Effects of fucoidan on catalepsy in PD rats (S115, S119)

Rasagiline 0.3 mg/kg · MATERIALS AND METHODS > Experimental design (S16, S17, S20); MATERIALS AND METHODS > In situ studies of mitochondrial respiratory function (S87); RESULTS > Effects of fucoidan on catalepsy in PD rats (S119)

Rasagiline and immobility in knockout mice

Animal study · CD157 KO mice [3]

CD157 KO mice received a single subcutaneous injection of Rasagiline. Rasagiline reduced immobility time in the FST compared with saline-treated CD157 KO mice.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
total duration of immobility during the last 4 min of the testReported result A single administration of rasagiline (Ras; 1, 10 mg/kg, s.c.) reduced immobility time of CD157 KO mice in the FST.[3]

Conditions shared by the study groups

Route
s.c. injection
Treatment course
single s.c. injection; 1 h after the last injection
Vehicle
saline
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Rasagiline 1 or 10 mg/kgsaline-treated CD157 KO miceA single administration of rasagiline (Ras; 1, 10 mg/kg, s.c.) reduced immobility time of CD157 KO mice in the FST.[3]
Rasagiline 1 or 10 mg/kg
Model: CD157 KO mice
Methods and source locations

Compound reported in the paper: Rasagiline

Evidence for Rasagiline as the mesylate form reported in the paper, not the free base/neutral form supplied as A11111; no salt equivalence, dose conversion or lot validation.

Materials and Methods > Drugs (S10, S14); Materials and Methods > Forced Swimming Test (FST) (S16); Figure 1 legend (S111)

total duration of immobility during the last 4 min of the test: total duration of immobility during the last 4 min of the test; comparator: saline-treated CD157 KO mice — Materials and Methods > Forced Swimming Test (FST) (S16); Figure 1 legend (S111)

Rasagiline 1 or 10 mg/kg · Materials and Methods > Drugs (S10, S14); Figure 1 legend (S111)

Rasagiline and dopamine metabolite levels during MPTP treatment

Animal study · male C57/Bl6 mice [1]

Male C57/Bl6 mice received a single intraperitoneal pretreatment with Rasagiline before MPTP treatment. In the presence of MPTP, Rasagiline did not restore dopamine metabolite levels and further decreased DOPAC and HVA levels.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
endogenous dopamine metabolite (DOPAC, HVA) levelsReported result Rasagiline (10 mg/kg i.p.), did not restore the level of metabolites in the presence of MPTP, but further decreased the level of DOPAC and HVA.[1]

Conditions shared by the study groups

Route
i.p.
Treatment course
a single i.p. pretreatment; 18 h before the start of MPTP treatment; 72 h after the last MPTP treatment
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Rasagiline 10 mg/kgMPTP treatedRasagiline (10 mg/kg i.p.), did not restore the level of metabolites in the presence of MPTP, but further decreased the level of DOPAC and HVA.[1]
Rasagiline 10 mg/kg
Model: male C57/Bl6 mice
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Rasagiline

Evidence for Rasagiline as the mesylate form reported in the paper, not the free base/neutral form supplied as A11111; no salt equivalence, dose conversion or lot validation.

Results > The protective effect of the compounds in acute MPTP-induced striatal dopamine depletion and motor deficit in mice (S20, S21, S34); Methods > In vivo acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model (S138, S139); Fig. 4 legend (S268, S271)

endogenous dopamine metabolite (DOPAC, HVA) levels: endogenous dopamine metabolite (DOPAC, HVA) levels; comparator: MPTP treated — Results > The protective effect of the compounds in acute MPTP-induced striatal dopamine depletion and motor deficit in mice (S34); Fig. 4 legend (S268)

Rasagiline 10 mg/kg · Results > The protective effect of the compounds in acute MPTP-induced striatal dopamine depletion and motor deficit in mice (S20, S21, S34); Methods > In vivo acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model (S139)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 136236-51-6
Applications MAO B inhibitor
Formula C12H13N
Molecular Weight 171.2
SMILES
C#CCN[C@@H]1CCC2=CC=CC=C12

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 30 mg/mL (175.19 mM)
Water 3 mg/mL (17.51 mM)
Ethanol 30 mg/mL

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Rasagiline Research References

  1. [1] Baranyi M, Porceddu PF, Gölöncsér F, et al. Novel (Hetero)arylalkenyl propargylamine compounds are protective in toxin-induced models of Parkinson's disease. Mol Neurodegener (2016). PMID: 26758813 DOI: 10.1186/s13024-015-0067-y Source material
  2. [2] Zhang L, Hao J, Zheng Y, et al. Fucoidan Protects Dopaminergic Neurons by Enhancing the Mitochondrial Function in a Rotenone-induced Rat Model of Parkinson's Disease. Aging Dis (2018). PMID: 30090649 DOI: 10.14336/AD.2017.0831 Source material
  3. [3] Kasai S, Yoshihara T, Lopatina O, et al. Selegiline Ameliorates Depression-Like Behavior in Mice Lacking the CD157/BST1 Gene, a Risk Factor for Parkinson's Disease. Front Behav Neurosci (2017). PMID: 28515684 DOI: 10.3389/fnbeh.2017.00075 Source material

Added to your cart

View Cart Checkout
Loading...